What is Alto Neuroscience's accrued research?

Alto Neuroscience (ANRO) reported accrued research of $3.14M in Q1 2026.

How has Alto Neuroscience's accrued research changed year-over-year?

Alto Neuroscience's accrued research increased by 51.1% year-over-year, from $2.08M to $3.14M.

Over 2 years (2023 to 2025), Alto Neuroscience's accrued research has grown at a -4.5% compound annual growth rate (CAGR), from $2.33M to $2.12M.

Operating income-$27.1M-73.1%

Net income-$26.2M-73.0%

EPS (diluted)-$0.80-42.9%

Cash & equivalents$264.3M+63.9%

Total debt$20.9M-17.2%

Total equity$243.4M+75.0%

Total assets$276.3M+60.7%

Operating cash flow-$27.1M-63.6%

CapEx$556.0K+2,217%

Free cash flow-$27.6M-66.7%

Market cap$887.88M+1,358%

Enterprise value$644.49M-958%

Return on equity-38.9%+0.9pp

Debt / equity0.1×-0.1×

Current ratio20.5×-2.0×

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept alto:AccruedResearchExpense.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Alto Neuroscience's accrued research?: Alto Neuroscience (ANRO) reported accrued research of $3.14M in Q1 2026.
How has Alto Neuroscience's accrued research changed year-over-year?: Alto Neuroscience's accrued research increased by 51.1% year-over-year, from $2.08M to $3.14M.
What is the long-term trend for Alto Neuroscience's accrued research?: Over 2 years (2023 to 2025), Alto Neuroscience's accrued research has grown at a -4.5% compound annual growth rate (CAGR), from $2.33M to $2.12M.